Hemangiopericytoma

Summary

Hemangiopericytoma (MONDO:0005094) is a disease (an umbrella term covering 8 Mondo subtypes) and 5 clinical trials. Top therapeutic interventions include dasatinib anhydrous. A subtype of hemangiopericytic tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 8 Mondo subtypes
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hemangiopericytoma
Mondo ID	MONDO:0005094
MeSH	D006393
DOID	DOID:264
NCIT	C3087
SNOMED CT	134335004
UMLS	C0018922
MedGen	5478
Is cancer (heuristic)	no

Also known as: haemangiopericytic meningioma [obs] · hemangiopericytoma · hemangiopericytoma, malignant (morphologic abnormality) · malignant hemangiopericytoma

Data availability: 2 cell lines.

Disease family

An umbrella term covering 8 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › pericytic neoplasm › hemangiopericytic tumor › hemangiopericytoma

Subtypes (8): kidney hemangiopericytoma, meninges hemangiopericytoma, breast hemangiopericytoma, retroperitoneal hemangiopericytoma, heart malignant hemangiopericytoma, adult intracranial malignant hemangiopericytoma, hemangiopericytoma, malignant, hemangiopericytoma of skin

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
Not specified	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00464620	PHASE2	COMPLETED	Trial of Dasatinib in Advanced Sarcomas
NCT01117844	PHASE1/PHASE2	COMPLETED	Proton Radiation For Meningiomas and Hemangiopericytomas
NCT03016091	PHASE2	TERMINATED	A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
NCT04648462	Not specified	RECRUITING	Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
NCT05259605	Not specified	RECRUITING	Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DASATINIB ANHYDROUS	4	2
CHEMBL4583196	0	1